PURPOSE: Primary hyperparathyroidism is a common endocrine disorder which is diagnosed biochemically and for which therapy is surgical. A prerequisite for minimally invasive surgery, which minimizes morbidity and cost, is accurate localization of the involved gland(s). The aim of this study was to evaluate the usefulness of (18)F-fluorocholine PET/CT for preoperative localization of hyperfunctioning parathyroid tissue. METHODS: (18)F-Fluorocholine PET/CT and conventional parathyroid scintigraphic imaging consisting of (99m)Tc-sestaMIBI SPECT/CT, (99m)Tc-sestaMIBI dual-phase imaging and (99m)Tc-sestaMIBI/pertechnetate subtraction imaging were performed in 24 patients. The diagnostic performance of the imaging methods was compared against histology as the gold standard and postoperative serum Ca(2+) and iPTH values. RESULTS: The sensitivity and specificity of (18)F-fluorocholine PET/CT were 92% and 100%, respectively, in contrast to 49% and 100%, 46% and 100%, and 44% and 100% for (99m)Tc-sestaMIBI SPECT/CT, (99m)Tc-sestaMIBI/pertechnetate subtraction imaging and (99m)Tc-sestaMIBI dual-phase imaging, respectively. Combined conventional scintigraphic imaging had a sensitivity and specificity of 64% and 100%, respectively. The performance of (18)F-fluorocholine PET/CT was superior particularly in patients with multiple lesions or hyperplasia. CONCLUSION: (18)F-Fluorocholine PET/CT appears to be a promising, effective imaging method for localization of hyperfunctioning parathyroid tissue.
PURPOSE:Primary hyperparathyroidism is a common endocrine disorder which is diagnosed biochemically and for which therapy is surgical. A prerequisite for minimally invasive surgery, which minimizes morbidity and cost, is accurate localization of the involved gland(s). The aim of this study was to evaluate the usefulness of (18)F-fluorocholine PET/CT for preoperative localization of hyperfunctioning parathyroid tissue. METHODS: (18)F-Fluorocholine PET/CT and conventional parathyroid scintigraphic imaging consisting of (99m)Tc-sestaMIBI SPECT/CT, (99m)Tc-sestaMIBI dual-phase imaging and (99m)Tc-sestaMIBI/pertechnetate subtraction imaging were performed in 24 patients. The diagnostic performance of the imaging methods was compared against histology as the gold standard and postoperative serum Ca(2+) and iPTH values. RESULTS: The sensitivity and specificity of (18)F-fluorocholine PET/CT were 92% and 100%, respectively, in contrast to 49% and 100%, 46% and 100%, and 44% and 100% for (99m)Tc-sestaMIBI SPECT/CT, (99m)Tc-sestaMIBI/pertechnetate subtraction imaging and (99m)Tc-sestaMIBI dual-phase imaging, respectively. Combined conventional scintigraphic imaging had a sensitivity and specificity of 64% and 100%, respectively. The performance of (18)F-fluorocholine PET/CT was superior particularly in patients with multiple lesions or hyperplasia. CONCLUSION: (18)F-Fluorocholine PET/CT appears to be a promising, effective imaging method for localization of hyperfunctioning parathyroid tissue.
Authors: Ken Herrmann; Toshiki Takei; Kakuko Kanegae; Tohru Shiga; Andreas K Buck; Jennifer Altomonte; Markus Schwaiger; Tibor Schuster; Kenichi Nishijima; Yuji Kuge; Nagara Tamaki Journal: Mol Imaging Biol Date: 2009-04-02 Impact factor: 3.488
Authors: D R Neumann; C B Esselstyn; W J Maclntyre; R T Go; N A Obuchowski; E Q Chen; A A Licata Journal: J Nucl Med Date: 1996-11 Impact factor: 10.057
Authors: Désirée Deandreis; Marie Terroir; Abir Al Ghuzlan; Amandine Berdelou; Ludovic Lacroix; François Bidault; Frederic Troalen; Dana Hartl; Jean Lumbroso; Eric Baudin; Martin Schlumberger; Sophie Leboulleux Journal: Eur J Nucl Med Mol Imaging Date: 2015-08-09 Impact factor: 9.236
Authors: Arnoldo Piccardo; P Trimboli; M Rutigliani; M Puntoni; L Foppiani; L Bacigalupo; Anna Crescenzi; G Bottoni; G Treglia; F Paparo; P Del Monte; M Lanata; G Paone; G Ferrarazzo; U Catrambone; A Arlandini; L Ceriani; M Cabria; L Giovanella Journal: Eur J Nucl Med Mol Imaging Date: 2018-09-15 Impact factor: 9.236
Authors: Arthur Varoquaux; Electron Kebebew; Fréderic Sebag; Katherine Wolf; Jean-François Henry; Karel Pacak; David Taïeb Journal: Endocr Relat Cancer Date: 2016-07-12 Impact factor: 5.678
Authors: Giorgio Treglia; Arnoldo Piccardo; Alessio Imperiale; Klaus Strobel; Philipp A Kaufmann; John O Prior; Luca Giovanella Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-09 Impact factor: 9.236
Authors: Serena Grimaldi; Jacques Young; Peter Kamenicky; Dana Hartl; Marie Terroir; Sophie Leboulleux; Amandine Berdelou; Julien Hadoux; Segolene Hescot; Hervé Remy; Eric Baudin; Martin Schlumberger; Désirée Deandreis Journal: Eur J Nucl Med Mol Imaging Date: 2018-04-22 Impact factor: 9.236
Authors: Arnoldo Piccardo; Gianluca Bottoni; Luis Alejandro Boccalatte; Chiara Camponovo; Martina Musumeci; Lorenzo Bacigalupo; Carlos Collaud; Martina Ugolini; Francesco Fiz; Pierpaolo Trimboli Journal: Endocrine Date: 2021-06-25 Impact factor: 3.633
Authors: G F Huber; M Hüllner; C Schmid; A Brunner; B Sah; D Vetter; P A Kaufmann; G K von Schulthess Journal: Eur Radiol Date: 2018-01-25 Impact factor: 5.315